Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Randomized, Double-blind, Placebo-controlled, 6 Month Clinical Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Trial Profile

A Single-center, Randomized, Double-blind, Placebo-controlled, 6 Month Clinical Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibudilast (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Acronyms IBU-ALS-1201
  • Sponsors MediciNova
  • Most Recent Events

    • 29 Jul 2019 According to a MediciNova media release, data (n=51;the intent-to-treat/ITT population) from the study were earlier presented at the 29thInternational Symposium on ALS/MND in December 2018..
    • 29 Jul 2019 According to a MediciNova media release, data from the study will be presented at the 30th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease).
    • 31 Jul 2018 According to a MediciNova media release, an abstract regarding this trial (extension) has been accepted for oral presentation at the 29th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) and will be presented by principal investigator Dr. Benjamin Rix Brooks.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top